Advisory Board

William Haseltine, Ph.D., Chairman

William A. Haseltine, Ph.D. became a scientific advisor to Calysta in 2013. He is Chairman and President of ACCESS Health International, Inc ( a foundation that supports access to affordable, high quality health services in low, middle and high income countries. He is also President of the Haseltine Foundation for Science and the Arts. He was a professor at Harvard Medical School, The Dana Farber Cancer Institue, and the Harvard School of Public Health. He is known for his pioneering work on cancer, HIV/AIDS and genomics. He is the Founder of Human Genome Sciences, Inc and served as the Chairman and CEO of the Company. He is a member of the Advisory Board of the IE University, Madrid, the Advisory Council for the Koch Institute of MIT and the Life Sciences Foundation, a member of the Advisory Board of the Ragon Institute, the Innovation Council of NYU Shanghai University, a member of the Dean’s Council and the Advisory Board of the FXB Center for Health and Human Rights at the Harvard School of Public Health. He is a Lifetime Governor of the New York Academy of Sciences and a member of the Board of AID for AIDS International. He is a member of the Board of Trustees of the Brookings Institution, and a member of the Council on Foreign Relations. He is a member of the Advisory Board of the Metropolitan Opera, a member of the Director’s Council of the Museum of Modern Art, a patron of the Metropolitan Museum of New York, the Whitney Museum, the Guggenheim Museum, the Whitney Museum a member of Board of Directors of the Young Concert Artists, Inc. and the Youth Orchestra of the Americas.

David Maki

David Maki became a scientific advisor to Calysta in 2013. Mr. Maki has been involved in life science organizations for over 30 years and co-founded Altitude Life Science Ventures, a venture capital firm that seeks to identify and support early stage life science companies. Prior to founding Altitude, he served as a Principal with Perennial Ventures, and as a Vice President with Tredegar Investments. He previously spent almost two decades in intellectual property law, focusing on IP strategic planning for life science companies. He served as the senior partner within his firm’s biotechnology group, which represented more than 60 life science companies in a variety of disciplines, including protein and small molecule therapeutics, medical devices, diagnostic instrumentation, and bioinformatics. During his tenure, he also held the positions of Managing Partner and Financial Partner. Mr. Maki is known as an industry expert in the development and execution of intellectual property strategies in the life sciences arena. He has served as a Board member for a number of life science companies, and on the Washington Biotechnology Advisory Committee. He currently serves as an independent Director on the Board of Pulmatrix, Inc. and is Chairman of the Board of the Infectious Disease Research Institute.